Peneliti USC identifikasi senyawa yang menargetkan peradangan otak pada penyakit Alzheimer

Para ilmuwan di University of Southern California telah menemukan senyawa eksperimental yang dapat mengurangi peradangan otak berbahaya yang terkait dengan penyakit Alzheimer. Penelitian ini berfokus pada enzim cPLA2 dan orang-orang yang membawa gen APOE4 berisiko tinggi.

Para peneliti di University of Southern California mengidentifikasi senyawa yang secara selektif menghambat cPLA2, sebuah enzim yang dikaitkan dengan peradangan di otak. Temuan ini diterbitkan dalam jurnal npj Drug Discovery pada tahun 2026. Tim tersebut menghubungkan aktivitas cPLA2 yang lebih tinggi dengan risiko Alzheimer yang lebih besar di antara para pembawa gen APOE4, meskipun enzim tersebut juga mendukung fungsi otak yang normal.

Artikel Terkait

Microscopic illustration of protective microglia clearing amyloid plaques in an Alzheimer's brain model due to the OLE molecule
Gambar dihasilkan oleh AI

Study identifies OLE molecule that shifts microglia into a more protective state in Alzheimer’s models

Dilaporkan oleh AI Gambar dihasilkan oleh AI Fakta terverifikasi

Researchers in Spain and Switzerland report that an experimental molecule called OLE helped restore protective behavior in the brain’s immune cells in animal models of Alzheimer’s disease, reducing amyloid-related pathology and improving performance on memory and movement tests.

Researchers at the Indiana University School of Medicine have identified the enzyme IDOL as a potential new target for treating Alzheimer's disease. Laboratory studies showed that removing the enzyme from neurons reduced amyloid plaques and improved brain cell communication.

Dilaporkan oleh AI

A major analysis of genetic data has linked 127 gene locations to Alzheimer’s disease, including 48 previously unidentified ones. Researchers also flagged several genes as promising drug targets and highlighted changes in immune and nerve cells.

Researchers at the University of Kentucky report that overactive microglia—immune cells in the brain—can drive sleep loss in mice with amyloid plaques. In the study, temporarily depleting most microglia restored more than two hours of sleep per day, even though plaque levels did not change.

Dilaporkan oleh AI

A major Cochrane review of 17 clinical trials involving over 20,000 participants has concluded that drugs targeting amyloid beta in the brain provide no meaningful benefits for patients with mild cognitive impairment or early Alzheimer’s. These treatments also raise the risk of brain swelling and bleeding. Researchers urge a shift to alternative pathways for future treatments.

Situs web ini menggunakan cookie

Kami menggunakan cookie untuk analisis guna meningkatkan situs kami. Baca kebijakan privasi kami untuk informasi lebih lanjut.
Tolak